Skip to main content
. Author manuscript; available in PMC: 2022 May 15.
Published in final edited form as: Cancer Res. 2021 Sep 16;81(22):5589–5595. doi: 10.1158/0008-5472.CAN-21-1606

Figure 1. Epigenetic mechanisms and regulators that drive resistance to targeted cancer therapeutics.

Figure 1.

A. Therapeutic agents can activate cell autonomous and/or cell non-autonomous mechanisms to confer drug resistance in cancer. This may involve acquisition of novel mutations, enrichment of drug-tolerant persister cells, and microenvironment-mediated drug resistance. B. The illustration depicts transcription factors, DNA modifiers, and chromatin regulators that contribute to resistance against targeted cancer therapies.